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Abstract 23 
Preclinical studies involving 89Zr often report significant bone accumulation, which is associated 24 
with dissociation of the radiometal from the tracer. However, experiments determining the 25 
uptake of unbound 89Zr in disease models are not performed as routine controls. The purpose 26 
of the present study was to investigate the impact of free or weakly bound 89Zr on PET 27 
quantifications in disease models, in order to determine if such control experiments are 28 
warranted. Methods: Chemical studies were carried out to find a 89Zr compound that would 29 
solubilize the 89Zr as a weak chelate, thus mimicking free or weakly bound 89Zr released in 30 
circulation. 89Zr oxalate had the desired characteristics, and was injected into mice bearing 31 
FaDu and HT29 solid tumor xenografts, and mice infected in the lungs with the mold Aspergillus 32 
fumigatus, as well as in healthy controls (naïve). PET/CT and PET/MR imaging followed to 33 
quantify the distribution of the radionuclide in the disease models. Results: 89Zr oxalate was 34 
found to have a plasma half-life of 5.1 ± 2.3 h, accumulating mainly in the bones of all animals. 35 
Both tumor types accumulated 89Zr on the order of 2-4% ID/cm3, which is comparable to EPR-36 
mediated accumulation of certain species. In the aspergillosis model, the concentration of 89Zr 37 
in lung tissue of the naïve animals was 6.0 ± 1.1 %ID/g. This was significantly different from that 38 
of the animals with advanced disease, showing 11.6% ± 1.8 %ID/g. Conclusions: Given the high 39 
levels of 89Zr accumulation in the disease sites in the present study, we recommend control 40 
experiments mapping the biodistribution of free 89Zr in any preclinical study employing 89Zr 41 
where bone uptake is observed.  Aqueous 89Zr oxalate appears to be a suitable compound for 42 
such studies. This is especially relevant in studies where the tracer accumulation is based upon 43 
passive targeting, such as EPR.44 
1. Introduction 45 
 46 
89Zr is a popular radionuclide for the radiolabeling of monoclonal antibodies (mAbs) and similar 47 
proteins for PET imaging [1–5]. However, several studies on 89Zr-radiolabeled mAbs show 48 
significant bone uptake of 89Zr [2,6,7]. This uptake is often attributed to chelate instability, with 49 
89Zr being released during the long circulation time of the mAb [2]. Alternatively, Holland et al. 50 
suggested a metabolic process [8]. Regardless of the cause, the accumulation of radioactivity in 51 
bones is indicative of 89Zr that is no longer bound to the tracer. The presence of this unbound 52 
89Zr during a PET scan can potentially have a large impact on the interpretation of results, 53 
especially if it is accumulating at the disease site. In current practice however, appropriate 54 
control experiments are not reported. 55 
 56 
The biodistribution of free, or weakly chelated, 89Zr was investigated in healthy mice by Abou et 57 
al. using the chloride, oxalate, phosphate and citrate salts [9]. All salts were found to exhibit 58 
similar biodistribution and cause accumulation of 89Zr in the bones, except the phosphate, 59 
which localized to liver and spleen. This was attributed to poor solubility of the 89Zr phosphate. 60 
Holland et al. also found the activity from the 89Zr oxalate to show pronounced bone 61 
accumulation, but found 89Zr injected as the chloride to accumulate in the liver [8]. This was 62 
also attributed to the chloride being prone to hydrolysis and poor solubility. These studies both 63 
indicated that free, soluble 89Zr4+ will accumulate in bone. 64 
 65 
The nonspecific biodistribution of free 89Zr in clinically relevant disease models has not been 66 
investigated. However, given the large number of reports showing increased bone uptake in 67 
monoclonal antibody imaging, which indicates the presence of free 89Zr, knowledge of the 68 
distribution of free 89Zr in animal models of human disease is important. In tumors, the 69 
accumulation of naked or weakly chelated radiometals, such as 67Ga [10], and 64Cu [11], is well 70 
established. For this reason, 67Ga salts have a long history of use in tumor imaging. 67Ga 71 
distributes via binding to transferrin [10], and it is reasonable to suspect that the same pathway 72 
might be available for Zr4+, or ZrO2+ [12]. Accordingly, free 89Zr could show nonspecific tumor 73 
accumulation through this pathway, which might disturb the correct interpretation of 74 
accumulation data from mAb imaging. In addition, enhanced permeation and retention (EPR) 75 
dominated localization after metal association with endogenous serum proteins, such as 76 
albumin, may give rise to lesion uptake of free 89Zr [13,14]. As nanoparticles are typically 77 
thought to localize to tumors via EPR [15], the presence of free 89Zr may have consequences for 78 
the interpretation of tumor accumulation data for 89Zr-labeled nanoparticles. 79 
 80 
89Zr-labeled antibodies are not only in use for tumor imaging, but are also being investigated for 81 
the diagnosis of other diseases such as pulmonary aspergillosis. In Aspergillus fumigatus 82 
infections, an extracellular siderophore is excreted by the mold [16]. This was recently utilized 83 
by Petrik et al. in preclinical PET studies with 68Ga labeled siderophores TAFC and FSC [17,18]. 84 
These chelators exhibit multiple hydroxamate groups, similar to the most successful 89Zr 85 
chelator desferrioxamine B, which itself is a siderophore produced by streptomyces bacteria 86 
[19]. Such extracellular siderophores may take up free or weakly bound 89Zr and facilitate its 87 
accumulation in Aspergillus infected tissues. This accumulation, coupled with the EPR-mediated 88 
accumulation occurring as a result of inflammation and transferrin-receptor upregulation, could 89 
give a very significant PET signal from lung accumulation of free or weakly bound 89Zr in 90 
circulation in pulmonary aspergillosis. Therefore, knowledge of the biodistribution of free 89Zr 91 
in solid tumors as well as in other disease sites, such as A. fumigatus infected tissues, is crucial 92 
before initiating a preclinical positron emission tomography (PET) study with 89Zr. 93 
 94 
The aim of this work was to investigate the biodistribution of weakly chelated 89Zr in relevant 95 
murine disease models compared to their healthy controls. We set out to determine whether 1) 96 
free 89Zr exhibits accumulation in FaDu and HT29 tumor xenografts in mice and 2) whether 97 
biodistribution, especially in lungs, is significantly different between healthy animals and those 98 
with pulmonary aspergillosis. Further, the criteria for the injected 89Zr to be considered ‘free’, 99 
was that it was stable in solution and able to interact and associate with complexing molecules 100 
and other blood stream components. For this reason we also investigated a range of 101 
complexing ligands for their ability to restrict hydrolysis of 89Zr and allow chelation by 102 
diethylene triamine pentaacetic acid (DTPA).  103 
104 
2. Materials and Methods 105 
 106 
2.1. Materials 107 
Yttrium foils were purchased from Alfa Aesar. All solvents and chemicals were purchased from 108 
Sigma Aldrich. 89Zr was produced on a GE PETtrace Cyclotron. Radio-TLC was performed on a 109 
Raytest MiniGita Star. All TLC analyses were performed on silica gel 60 F254 plates (Merck) with 110 
5% (w/v) NH4OAc in H2O-MeOH (1:1) as eluent, in which the Rf of 89Zr-DTPA is 0.7 and 89Zr4+ 111 
does not elute. Radioactivity was measured using a Veenstra Instruments dose calibrator VDC-112 
505. QMA cartridges were from Waters. Osmolalities were measured on an Osmomat 030 113 
cryoscopic osmometer (Gonotec). pH was measured on an Inolab 740 electronic pH-meter 114 
(WTW). Radionuclidic purity was measured on an LGC-5 high purity germanium detector 115 
(Princeton Gamma-Tech). Metal ions were quantified with an ICAP 7000 ICP-OES (Thermo 116 
Scientific). Ultrapure water was used in all cases (Milli-Q water purification system, Millipore). 117 
 118 
89Zr chloride was prepared according to the method of Holland et al. [20]. In brief, natural 660 119 
µm thick yttrium foils, were irradiated with 15 µA of protons degraded from 16 MeV to 11 MeV 120 
with an 800 µm aluminum plate. The produced 89Zr4+ was separated from the yttrium target 121 
after digestion in aqueous HCl (3 mL, 6 M) by trapping on hydroxamate resin (50-100 mg), 122 
followed by elution of the 89Zr4+ in aqueous oxalic acid (3 mL, 1 M). A quarternary methyl 123 
ammonium Sep-Pak cartridge (QMA light, Waters) was used to trap the anionic 89Zr oxalate 124 
complex from the oxalic acid solution, and after washing with ultrapure water (30 mL), the 89Zr 125 
was released in aqueous HCl (200 µL, 2 M). This solution was taken to dryness under argon flow 126 
at 110 oC for 15 minutes, furnishing 89Zr chloride.  127 
 128 
2.2. Comparison of aqueous solutions for injection of ‘free’ 89Zr   129 
The following experiments were performed to test the ability of various complexing ligands to 130 
restrict hydrolysis of 89Zr and allow chelation by DTPA. To vials containing dry 89Zr chloride was 131 
added 1.3 mL of either 1) saline, 2) 10 mM oxalic acid in saline at pH ≈ 5.5, 3) 10 mM oxalic acid 132 
in saline at pH ≈ 7.0, 4) 10 mM citric acid in saline at pH 5.5, 5) 10 mM citric acid in saline at pH 133 
7.0, 6) neat ultrapure water, 7) isotonic sucrose solution at 924 mg/mL, 8) 10 mM sodium 134 
acetate at pH 5.5 or 9) 10 mM sodium acetate at pH ≈ 7.0. Each preparation was stirred for 10 135 
minutes at 37 oC after which 300 µL was removed for pH measurement. In addition, the 136 
radioactivity in the total volume (1.3 mL) as well as in the removed 300 µL was measured. To 137 
the remaining 1.00 mL was then added aqueous DTPA (50 µL, 50 mM) that had been adjusted 138 
to pH 5.5 or pH 7.0, whichever was closest to the pH of the receiving 89Zr-mixture. To the saline 139 
(chloride), water and sucrose mixtures was added DTPA at pH 5.5. The solutions were then 140 
stirred at 37 oC and monitored by radio-TLC with samples removed at t = 0 (before addition of 141 
DTPA), t = 10 min, t = 30 min and t = 60 min. Each mixture was prepared and analyzed in 142 
triplicate. 143 
 144 
2.3 Preparation and characterization of the 89Zr oxalate for in vivo use 145 
Based on the stability and exchange experiments described above, an oxalate solution was 146 
chosen for in vivo use. This was prepared by adding a solution of 10 mM oxalic acid in isotonic 147 
saline (pH adjusted to 6.7 with NaOH) to the dried 89Zr chloride. In order to confirm that the 148 
89Zr was fully dissolved, a sample of the solution was removed and its activity concentration 149 
was compared to the remaining fraction. Osmolality and pH were measured, and HPGE gamma 150 
spectroscopy was used to determine the radionuclidic purity. ICP-OES, calibrated against Fe, Zr, 151 
Zn, Cu, Ag, and Ni standards in 1% (w/v) HCl, was used to quantify metal impurities. 152 
Additionally, 300 µl of the 89Zr oxalate solution was removed and mixed with aqueous DTPA (15 153 
µL, 50mM, pH 7.0). After stirring at 37 oC for 30 min, it was analyzed by radio-TLC along with a 154 
sample to which no DTPA had been added. After the completion of these tests, the solution 155 
was ready for injection in the animal studies. 156 
 157 
2.4 In vivo studies on tumor-bearing mice 158 
The studies on tumor-bearing mice were approved by the Danish Animal Welfare Council, 159 
Ministry of Justice. Human head and neck cancer cell line, FaDu and human colorectal cancer 160 
cell line, HT29 (purchased from ATCC) were cultured in MEM medium with Earle’s salts and 161 
McCoy’s 5A medium, respectively (both from Sigma-Aldrich); with 10% fetal calf serum, and 162 
100 units/mL penicillin and 100 μg/mL streptomycin (Invitrogen) at 37 °C in 5% CO2. In addition 163 
the MEM medium was supplemented with 1% MEM non-essential amino acids solution (100x), 164 
1 mM sodium pyruvate (both from Invitrogen) and 2 mM L-glutamine (Sigma-Aldrich). Tumors 165 
were established in the left and right flank of seven-week old female NMRI nude mice (Taconic 166 
Europe) by subcutaneous injection of 106 cancer cells dissolved in 200 µL of a 1:1 mixture of 167 
MatrigelTM (BD-Biosciences) and growth medium and were allowed to grow for 2-3 weeks for 168 
tumor volumes of 50-500 mm3. Animals had access to chow and water ad libitum. For tracer 169 
administration and during scans, the mice were placed in a nose cone and breathed gas 170 
anesthesia (2.5% Sevoflorane (Abbot Scandinavia) mixed with 35% O2 in N2). A heating pad was 171 
used to keep the body temperature stable. 89Zr oxalate solution (100 µL, 9-15 MBq) was 172 
injected into the tail vein of mice bearing FaDu (n = 3) and HT29 tumor xenografts (n = 4). Ten 173 
minute static scans were performed on a small animal PET scanner (microPET 120, Siemens 174 
Medical Solutions) at 1 h, 6 h, 20 h, 45 h, and 68 h post injection with an energy window 350-175 
650 keV and 6 ns time resolution. Each PET scan was followed by seven minutes small animal CT 176 
scans (MicroCAT II Tomograph; Siemens Medical Solutions) with tube voltage and tube current 177 
set at 70 kVp and 500 μA, respectively and an exposure time of 310 ms per projection (360°; 178 
360 projections). Listmode data from PET acquisitions were post-processed into sinograms and 179 
reconstructed using the maximum a posteriori (MAP) algorithm. Images had a resolution of 1.2 180 
mm at the center field of view. PET and CT images were fused using Inveon software (Siemens 181 
Medical Solutions), ROIs were drawn on different target tissue and uptake quantified as % 182 
injected dose per cubic centimeter (%ID/cm3). Additionally, the tumor-to-muscle (T/M) and 183 
tumor-to-blood (T/B) ratios were calculated. From the images it was evident that the 184 
myocardium did not accumulate high levels of 89Zr oxalate. As it is impossible to delineate the 185 
left ventricle of the mice based on CT scans without contrast, a ROI created on the heart was 186 
used for T/B-ratio and blood-circulation half-life calculations. 187 
 188 
2.5 In vivo studies on A. fumigatus infected and naïve mice 189 
The studies on A. fumigatus infected and disease-free control mice (“naïve”) were performed 190 
according to the German Animal Protection Law with permission from the responsible local 191 
authorities. Infections were performed as described by Bruns et al [21]. Briefly, eight-week old 192 
female C57BL/6 mice (Harlan Laboratories) were rendered neutropenic by an intraperitoneal 193 
injection of 100 μL anti-Gr-1 antibody solution (clone RB6-8C5 at a concentration of 1 mg/mL, 194 
BioXCell). 24 h later a pulmonary A. fumigatus infection was induced by an intratracheal 195 
application of 4x106 resting A. fumigatus spores (strain ATCC 46645), suspended in 100 μL 196 
sterile tap water. For this step the animals were anaesthetized by an intraperitoneal injection of 197 
100 µL Ketamin/Rompun solution (Ketamin: 80 mg/kg, Ratiopharm GmbH, Ulm, Germany; 198 
Rompun: 15 mg/kg, Bayer HealthCare, Leverkusen, Germany). After reaching deep narcosis, the 199 
animals were intubated using a 22G indwelling venous catheter (Vasofix Braunüle, B. Braun AG, 200 
Melsungen, Germany) and subsequently the spore suspension was applied. To achieve a better 201 
distribution of the spore mass and to avoid suffocation the animals were ventilated for one 202 
minute with a small animal respirator (MiniVent, Hugo Sachs, March-Hugstetten, Germany) at a 203 
rate of 250 breaths per minute at an inhalation volume of 300 μL per breath. Animals had 204 
access to food and water ad libitum. 205 
 206 
89Zr oxalate solution (50 µL, 10-12 MBq), was injected via the lateral tail vein. During imaging, 207 
the animals were anesthetized with 1.5% isoflurane mixed with 100% oxygen. Anesthesia was 208 
monitored by measuring the respiratory frequency, and the body temperature was kept at 37°C 209 
by a heating pad. All mice were imaged using a small animal PET scanner (Inveon, Siemens 210 
Preclinical Solutions), yielding a spatial resolution of approximately 1.3 mm. PET data were 211 
acquired in list-mode, histogrammed in one 10 min time frame for the static scans and 212 
reconstructed using an iterative ordered subset expectation maximization (OSEM) algorithm. 213 
No attenuation correction was applied. Magnetic resonance (MR) imaging was performed on a 214 
7 T small animal MR tomograph (Clinscan, Bruker Biospin MRI) obtaining anatomical 215 
information for optimized organ delineation. A T2-weighted 3D space sequence (TE / TR 202 / 216 
2500 ms, image matrix of 137 x 320, slice thickness 0.27 mm) was used for whole-body imaging. 217 
PET images were normalized to each other, subsequently fused to the respective MR images 218 
and analyzed using Inveon Research Workplace software (Siemens Preclinical Solutions). 219 
Results are expressed as percentage of the injected dose per cm3 (%ID/cm3). After the last PET 220 
scan, the animals were sacrificed by cervical dislocation under deep anesthesia and dissected. 221 
Organs were removed, weighed and measured with an aliquot of injected solution in the γ-222 
counter (Wizard single-detector γ-counter; Perkin Elmer) using an energy window between 350 223 
and 650 keV. 224 
 225 
The A. fumigatus infected mice were divided into two different groups. The first group (n = 5), 226 
termed “nascent disease”, received the tracer injection immediately after infection. These 227 
animals, along with neutropenic uninfected controls (n = 5), “naïve”, mice were imaged with 10 228 
min PET scans, followed by MR imaging, performed at 3, 24 and 48 h post-injection of the 229 
tracers. In the second group (n = 4), termed “advanced disease”, infected mice were injected 230 
with 89Zr oxalate 21 hours after infection. This cohort, along with four naïve control animals, 231 
was imaged 3 h after tracer injection, followed immediately by ex vivo biodistribution. 232 
 233 
2.6 Statistical Analysis 234 
Statistical analysis was performed using a two-tailed t-test. Data were considered statistically 235 
significant for p < 0.05. All quantitative results are shown as the mean ± 1 standard deviation 236 
(SD). 237 
238 
3. Results 239 
 240 
3.1 Comparison of aqueous solutions for injection of ‘free’ 89Zr 241 
The results from the tests on the various 89Zr-mixtures are presented in table 1 (pH values for 242 
the mixtures) and figures 1A (transferability/dissolution) and 1B (transchelation to DTPA). For 243 
the pH measurements in general, the solutions with low buffer capacity at their respective pH 244 
values became slightly more acidic after mixing with the dried 89Zr activity. This was likely due 245 
to leftover oxalic acid residue from the chemical separation. Our lowest water pH measurement 246 
was pH = 4.65, which indicates that oxalic acid concentration was less than 13 µM (see 247 
supplemental materials for calculation). According to the work of Kobayashi et al. [22], Zr4+ is 248 
present as the insoluble hydroxide complex at such low oxalate concentrations. This was 249 
reflected by our transferability tests (figure 1A). In solutions with an efficient complexing agent 250 
in sufficient concentration to restrict hydrolysis, such as oxalate, citrate, or sucrose, 89Zr was 251 
readily taken into the aqueous phase, whereas hydrolysis-prone mixtures, such as water, 252 
acetate, and chloride, resulted in incomplete dissolution of the 89Zr. 253 
 254 
Despite the fact that several solutions were able to bring 89Zr into the aqueous environment, it 255 
remained necessary to test whether the 89Zr was still able to transchelate to DTPA. This would 256 
ensure that the 89Zr was not merely suspended as a colloid, and that the complexes in question 257 
could easily transfer the radioactivity to other agents. All complexes were tested for 258 
transchelation to DTPA, but only the ones with superior transferability are shown in figure 1B. 259 
For the remainder, please refer to supplemental materials. Both oxalate mixtures showed fast 260 
and efficient transchelation to DTPA, within 10 minutes. On the other hand, the uptake from 261 
the citrate was markedly slower, showing a gradual ascent, reaching about 70-80% after one 262 
hour. DTPA chelation from the sucrose was faster than from the citrate, but slower than from 263 
the oxalate. 264 
 265 
Based on the results described above, we decided to use the oxalate complex for in vivo 266 
studies, while keeping the pH below 7. The main reason for choosing oxalate over citrate was 267 
that we desired a complex with a higher propensity for transferring 89Zr to other chelating 268 
agents present in serum. This was expected to prevent fast renal clearance of the charged 269 
complexes and to better mirror the in vivo situation where weakly bound 89Zr is released and 270 
presumably bound to endogenous serum components. 271 
 272 
3.2 Preparation and characterization of the 89Zr oxalate solution for in vivo use  273 
The results of the quality control analyses for the injected 89Zr oxalate solutions were consistent 274 
with those observed in the transferability/solubility and transchelation tests described above. 275 
The transferability of activity in the 89Zr oxalate in vivo formulation was 95%, indicating that the 276 
89Zr was properly dissolved. The pH value was in the range of 5.5-6.7, which due to the low 277 
buffer capacity of the solution was expected to fluctuate. The osmolality was 310 mOsmol/kg, 278 
and was appropriate for injection (serum osmolality: 282 - 295 mOsmol/kg). Analysis by ICP-279 
OES showed both non-radioactive Zr and Fe to each be present in concentrations on the order 280 
of 200 ppb. This gave specific activities against total Zr and Fe of 20-35 GBq/µmol at time of 281 
injection. Analysis by gamma spectroscopy showed only peaks originating from 89Zr, indicating 282 
radionuclidic purity over 99%. Analysis of the 89Zr oxalate solution by radio-TLC showed that 283 
>99% of the activity stayed at the origin. Following addition of DTPA, 98% of the activity shifted 284 
to the Zr-DTPA peak after 30 minutes (93% after 10 minutes). This confirmed a radiochemical 285 
purity of >95%, and that the activity was freely transchelated from the oxalate complex to other 286 
chemical species.  287 
 288 
3.3 In vivo data from tumor-bearing mice 289 
Representative PET/CT images from the FaDu and HT29 tumor-bearing animals are given in 290 
Figure 2, with organs denoted. Tumor contrast is clearly seen at both 1 h and 45 h. However, 45 291 
h images are dominated by high bone accumulation. 292 
 293 
Quantifications of the PET data are given in Table 2. Both tumor types showed significant 294 
uptake of 2-4% ID/cm3 over the course of the study. As expected, bone uptake was prominent, 295 
reaching a maximum at 20 h, followed by a plateau at around 13% ID/cm3. The tumor-to-296 
muscle (T/M) and tumor-to-blood (T/B) ratios in each tumor model are displayed in Figure 3. 297 
The T/M values ranged from 1.5-3.7 at all time-points, reflecting the contrast observed in 298 
Figure 2. The long circulation time of the 89Zr oxalate is evident in the heart ROI data. To obtain 299 
the clearance half-life, the heart ROI time activity curve for each animal was fitted with an 300 
exponential function (unweighted least squares fit with constant background). The average (± 1 301 
SD) blood clearance half-life was 5.1 ± 2.3 h (n = 7) (refer to supplemental materials for 302 
calculation).  303 
 304 
3.4 In vivo data from Aspergillus-infected mice and healthy controls 305 
The mice infected with A. fumigatus were divided into two groups. In the nascent disease 306 
group, where animals received the tracer injection immediately after they had been infected, 307 
and their naïve controls, the PET and biodistribution data were independent of disease status 308 
(Figure 4A-D). Quantification of the PET results revealed enhanced uptake of 89Zr in the spine 309 
(Figure 4C) without significant differences between the tested groups. The bone uptake pattern 310 
is evident by qualitative observation in the 48 h maximum intensity projection (MIP) images in 311 
Figure 4E. The mean tracer uptake in the spine of naïve mice increased from 7.5 ± 0.9 %ID/cm3 312 
at 3 h to 18.6 ± 1.0% ID/cm3 at 24 h, and in infected animals from 7.5 ± 0.3 % ID/cm3 at 3 h to 313 
16.5 ± 1.6 % ID/cm3 at 24 h after tracer injection, further reflecting the similarity between 314 
infected and naïve animals.  315 
 316 
Contrastingly, for the group of animals with advanced disease, those infected with A. fumigatus 317 
21 hours prior to tracer injection, the biodistributions were markedly different from the healthy 318 
controls. Static PET images at 3 hours post injection (Figure 5) revealed significantly higher 319 
uptake of 89Zr (7.8 ± 1.3 %ID/cm3) in the lungs of A. fumigatus infected animals compared to the 320 
naïve group (5.7 ± 0.3 %ID/ cm3; p = 0.048, Figure 6) In addition, the uptake of 89Zr in the spine 321 
of naïve animals was significantly higher (6.5 ± 0.7 %ID/cm3)  compared to the infected group 322 
(4.8 ± 0.3 %ID/cm3; p = 0.0088, Figure 6). No significant differences were seen in liver and 323 
muscle tissues (Figure 6).  324 
 325 
 326 
The ex vivo biodistribution from the advanced disease group confirmed the quantification 327 
obtained from the PET imaging (Table 3). The data from all animals revealed high 328 
concentrations of 89Zr in the bones, blood, and highly blood-perfused organs such as the heart. 329 
The %ID/g values of the blood were 10.5 ± 2.7 (naïve animals) and 8.6 ± 2.8 (advanced disease). 330 
The ex vivo biodistribution confirmed the significant differences in the lung (p = 0.002) and 331 
spine (p = 0.045) uptake between the infected and naïve animals observed with in vivo PET 332 
quantification. 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
4 Discussion 347 
 348 
89Zr has a half-life of 3.27 days and is therefore a useful radionuclide for elucidating the 349 
biodistribution of long-circulating, biologically relevant molecules, such as antibodies and 350 
nanoparticles.  Currently, it is one of the most widely used nuclides for PET imaging at time-351 
points beyond two days post-injection. It allows researchers to understand how a labeled 352 
molecule distributes, giving useful information that leads to better drug and tracer 353 
development.  354 
 355 
The weakness in the current practice is that the derived images quantify the distribution of the 356 
radionuclide and not necessarily the intact tracer. In general this is a well-understood 357 
phenomenon in PET that can be controlled for by metabolite analysis. However, in 89Zr imaging 358 
the problem is rarely addressed. This is surprising because in a large number of pre-clinical 359 
studies involving 89Zr there is heightened bone accumulation in the animals. Such high skeletal 360 
uptake is indicative of 89Zr that is no longer bound to the molecule of interest, but is free or 361 
weakly coordinated. Given that there is an observed separation between radionuclide and the 362 
traced molecule, it is important to understand how the free radionuclide is affecting the PET 363 
data. 364 
 365 
In PET imaging of antibodies 89Zr is usually located in the desferrioxamine (Df) chelator. Within 366 
Df, it is present as 89Zr4+, with water taking up the remaining coordination sites rather than =O 367 
or –OH [8]. This incomplete occupation of the first coordination shell by Df has been pointed to 368 
as a chink in the armor of an otherwise incredibly stable chelate, and a possible cause for 369 
release of free 89Zr in preclinical studies [23]. Another reason for the presence of free 89Zr in 370 
mAb studies is non-specific binding of the radiometal to the protein. Often, radiolabeling is 371 
reported with less than 100% yield [6,7], which means either that Df-chelation sites were in 372 
shortage or that the reaction had not run to completion. In such cases surplus 89Zr will be 373 
present in the reaction mixture and it is reasonable to assume that some of it could bind non-374 
specifically to certain proteins. Finally, it is possible that free 89Zr arises from metabolism of the 375 
radiolabeled entities. 376 
 377 
Regardless of the mechanism by which 89Zr is released to the circulation, we sought a tracer 378 
that would solubilize and efficiently disperse the 89Zr while restricting irreversible hydrolysis. 379 
We found that a solution of the radioactivity in 10 mM oxalate in isotonic saline with a pH of 380 
5.0-6.5 adequately provided the desired properties. This was shown by the high solubility of the 381 
89Zr in the mixture and its rapid chelation by DTPA. In addition, the in vivo results showed 382 
limited liver accumulation. This is consistent with results reported by Abou et al. and by Holland 383 
et al. where 89Zr oxalate was not accumulating in the liver of healthy animals [8,9]. On this 384 
basis, we conclude that our injected 89Zr was adequately dissolved. Also, the plasma half-life of 385 
our injected activity was 5.1 ± 2.3 h. Usually, small molecular, exogenous, highly charged 386 
species, such as 89Zr oxalate, can be expected to undergo fast renal clearance, as is the case 387 
with free 89Zr-Df [8]. For this very reason, the short circulation time of 89Zr-Df makes it unsuited 388 
as a tracer for monitoring the biodistribution of weakly bound 89Zr. That the injected 389 
radioactivity in our studies showed prolonged retention in blood suggests that either the 390 
activity is shifted to other endogenous carriers with long circulation, or that the 89Zr oxalate 391 
itself is long-circulating. In both cases, since the oxalate is a weak complex, the long circulatory 392 
property of the activity is beneficial to its distribution via the routes that could be expected of 393 
89Zr weakly bound to long-circulating species, such as antibodies or nanoparticles.  394 
 395 
Our initial screening of 89Zr formulations revealed chloride (as saline) to inadequately prevent 396 
hydrolysis and keep 89Zr in solution, for which reason we deemed it unfit for in vivo use without 397 
an additional complexing ion. This agreed with the studies performed by Holland et al., where 398 
the chloride formulation was found to exhibit heavy liver accumulation [8]. In contrast, Abou et 399 
al. found the chloride (as saline) to distribute similarly to otherwise free 89Zr, with activity 400 
mainly localizing to bones [9]. Accordingly, there is a discrepancy between the results of these 401 
groups with regards to the chloride. Our study primarily supports the results for the chloride 402 
achieved by Holland et al. It is possible that traces of oxalic acid remaining after preparation of 403 
the chloride could aid in the solubilization and unrestricted biodistribution of 89Zr present in an 404 
otherwise chloride containing mixture. It should be noted that we employed the same method 405 
for preparing the 89Zr chloride as Holland et al., and therefore we could be expected to observe 406 
the same insolubility [8]. 407 
 408 
89Zr that is released in vivo has the opportunity of being taken up by endogenous binding 409 
agents. Likely candidates for such binding include transferrin (Tf) and albumin. Transferrin 410 
labeled with 89Zr through Df has been shown to accumulate in tumors and inflammations, due 411 
to the upregulation of transferrin receptors as part of an inflammatory response [24,25]. 412 
However, binding of 89Zr to the endogenous ferric binding site of transferrin without the use of 413 
a chelator was found to be less suitable for in vivo use by Holland et al. [24]. The conclusion 414 
that endogenous labeling was not viable as a method for producing stable 89Zr-Tf for in vivo 415 
imaging does not exclude the possibility of in vivo 89Zr transport via transferrin. The somewhat 416 
analogous labeling of transferrin by 45Ti, and its subsequent reported localization to tumors, 417 
indicates that tumor accumulation of hard, oxophilic radiometals can be due to binding to 418 
transferrin [26]. The results from the HT29 and FaDu tumor models presented here do not 419 
show the striking contrast (14.9 %ID/cm3 tumor accumulation at 24 h) observed by Vavere et al. 420 
for 45Ti-transferrin; albeit the difference could be attributed to the different affinities of 421 
transferrin toward the metals. However, the range of the tumor accumulations we observed 422 
are consistent with uptake based upon EPR, such as that of radiolabeled nanoparticles, which is 423 
usually in the range of 3-6 %ID/cm3 [27–29]. Albumin may be a vehicle for tumor accumulation 424 
of certain species such as radiometals or their hydroxides/oxides due to its metal binding 425 
capabilities [13]. Albumin has been labeled with 89Zr through desferrioxamine and gave a 426 
biodistribution in tumor-bearing animals that was dominated by EPR-mediated tumor 427 
accumulation, with tumor values of 2-5 %ID/cm3 measured until 20 h post injection [14]. While 428 
the level of tumor accumulation (2-4% ID/cm3) observed in the present study is negligible with 429 
respect to signals observed with many highly specific mAbs (eg. J591-PSMA in LnCaP 430 
xenografts, 34-46 %ID/cm3, [8]), it is not small compared to the uptakes expected in non-431 
targeted nanoparticle imaging. Therefore, as 89Zr becomes more prevalent in nanoparticle 432 
imaging, differentiating between the non-specific accumulation of free 89Zr, versus that of the 433 
nanoparticles, must be taken into account.  434 
 435 
As a further point, it should be noted that the impact of non-specific accumulation of free 89Zr 436 
in spontaneous human cancers is unknown. If free 89Zr exhibits tumor accumulation due to the 437 
EPR effect, translation from mice to humans may amplify the significance of non-specific 438 
uptake, especially in the case of imaging with 89Zr-labeled mAbs. When imaging EPR-localizing 439 
agents, an increased tumor accumulation relative to total body mass from mice to humans is 440 
typically seen. Harrington et al. investigated 111In-labeled liposomes and found tumor uptakes 441 
in mice ranging from 1-6 %ID/g over several days post-injection in an HNSCC-derived xenograft 442 
model [30]. In humans, they found a tumor uptake of 33 ± 16 %ID/kg at 72 hours [31]. On the 443 
contrary, targeted mAb imaging with U36 against HNX-OE (HNSCC-derived) xenografts in mice 444 
gave a striking uptake of 26±2 %ID/g at 144 hours[32], whereas the same mAb in humans with 445 
HNSCC had an average uptake of 19 %ID/kg[33]. From these data, it is apparent that uptake in 446 
man versus mouse is not directly scalable, but can depend on the mode of accumulation. 447 
Accordingly, we propose that if 89Zr localizes to tumors by transferrin binding and EPR uptake, 448 
the impact on proper assessment of tumor uptake may be greater in humans when imaging 449 
antibodies that primarily localize by active targeting. 450 
 451 
Finally, turning to the pulmonary aspergillosis model, the results illustrate that when imaging 452 
animals with advanced disease, the presence of free 89Zr cannot be neglected. This disease 453 
model was expected to give an uptake of free 89Zr that was significantly different from naïve 454 
animals for several reasons. First, as the disease progresses the lung tissue becomes highly 455 
perfused, thereby giving a higher PET signal due to blood volume in the ROI, and due to EPR 456 
localization. Second, the inflammation in the lungs would lead to an upregulation of the Tf-457 
receptor causing accumulation of 89Zr that might have been associated with transferrin in vivo. 458 
And lastly, higher uptake was expected due to the presence of cyclic hydroxamate-based 459 
chelates in the extracellular environment of the fungus. The results of the present study do not 460 
weigh in on which of these probable causes are responsible, yet they do set a benchmark for 461 
significance when attempting targeted approaches to pulmonary aspergillosis imaging.  462 
 463 
5 Conclusions 464 
 465 
In this study we have shown that free 89Zr, in the form of 89Zr oxalate in saline, can exhibit 466 
substantial tumor accumulation as well as significant accumulation in Aspergillus infected lungs 467 
as compared to healthy lungs. Our results underline the importance of making sure that no free 468 
89Zr is present when conducting 89Zr PET imaging, especially in cancers and pulmonary 469 
aspergillosis, as observed accumulation of radioactivity may be non-specific. In addition, our 470 
results indicate that injection of free 89Zr, preferably as an oxalate at pH < 7, should routinely be 471 
performed as a control experiment to a preclinical study. 472 
 473 
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  573 
Table 1. pH ranges of 89Zr complex preparations as measured after 10 minutes of mixing of 89Zr 574 
chloride with the corresponding solution. 575 
Mixture pH range 
Oxalate 5.5 4.87 – 6.01 
Oxalate 7.0 6.74 – 7.45 
Citrate 5.5 5.43 – 5.58 
Citrate 7.0 6.60 – 6.93 
Sucrose 5.12 – 6.77 
Acetate 5.5 5.51 – 5.52 
Acetate 7.0 6.43 – 7.54 
Chloride 4.99 – 5.68 
Water 4.65 – 4.95 
 576 
 577 
Table 2. Biodistribution of 89Zr, injected as the oxalate, in tumor-bearing mice. Averages and 578 
standard deviations are given (n = 3 for FaDu, n = 4 for HT29). Animals were injected 579 
intravenously with 89Zr oxalate and imaged for up to 68 h. Tumor levels were higher than muscle 580 
at all measurement points. Tumor levels were higher than blood (heart) after 45 h. Errors indicate 581 
one standard deviation. 9-15 MBq was administered to each mouse, 10 min scans were acquired   582 
 %ID/g (± SD) 
 Xenograft Heart Kidney Bladder Liver Tumor Muscle Bone 
1h 
All (n = 7) 10.59 (± 2.47)  4.69 (± 1.21) 4.04 (± 2.91) 6.07 (± 1.92) 2.99 (± 0.35) 1.98 (± 0.31) 4.30 (± 1.08) 
FaDu 11.83 (± 3.01) 5.55 (± 1.45) 2.93 (± 1.00) 7.40 (± 2.26) 2.97 (± 0.37) 2.03 (± 0.42) 4.53 (± 1.66) 
HT29 9.65 (± 1.84) 4.05 (± 0.48) 4.88(± 3.76) 5.08 (± 0.93) 3.00 (± 0.36) 1.94 (± 0.26) 4.13 (± 0.64) 
6h 
All (n = 7) 5.31 (± 2.42) 2.56 (± 1.09) 3.26 (± 0.91) 3.36 (± 1.69) 3.46 (± 0.65) 1.76 (± 0.46) 9.04 (± 2.59) 
FaDu 6.53 (± 2.95) 3.25 (± 1.31) 3.23 (± 1.46) 4.37 (± 2.02) 4.08 (± 0.41) 2.05 (± 0.55) 10.37 (± 3.58) 
HT29 4.40 (± 1.81) 2.04 (± 0.61) 3.28 (± 0.48) 2.60 (± 1.09) 2.99 (± 0.29) 1.54 (± 0.25) 8.05 (± 1.35) 
20h 
All (n = 7) 1.86 (± 1.49) 1.35 (± 0.68) 1.05 (± 0.28) 1.77 (± 1.33) 2.99 (± 1.22) 0.99 (± 0.40) 12.76 (± 2.24) 
FaDu 3.07 (± 1.47) 1.85 (± 0.77) 1.15 (± 0.34) 2.77 (± 1.46) 4.13 (± 0.96) 1.37 (± 0.23) 13.63 (± 1.56) 
HT29 0.95 (± 0.65) 0.97 (± 0.31) 0.97 (± 0.25) 1.03 (± 0.60) 2.14 (± 0.40) 0.71 (± 0.18) 12.10 (± 2.65) 
45h 
All (n = 7) 0.67 (± 0.56) 0.91 (± 0.44) 0.60 (± 0.22) 1.39 (± 0.99) 2.47 (± 0.95) 0.76 (± 0.36) 14.89 (± 1.32) 
FaDu 1.09 (± 0.67) 1.24 (± 0.53) 0.72 (± 0.32) 2.14 (± 1.19) 3.27 (± 0.97) 1.07 (± ) 0.36 13.17 (± 0.78) 
HT29 0.35 (± 0.09) 0.66 (± 0.10) 0.50 (± 0.04) 0.83 (± 0.26) 1.88 (± 0.23) 0.53 (± 0.10) 15.58 (± 1.25) 
68h 
All (n = 7) 0.55 (± 0.31) 0.86 (± 0.32) 0.50 (± 0.08) 1.30 (± 0.82) 2.05 (± 0.76) 0.65 (± 0.29) 12.99 (± 1.45) 
FaDu 0.86 (± 0.14) 1.00 (± 0.40) 0.54 (± 0.08) 1.93 (± 0.92) 2.72 (± 0.74) 0.78 (± 0.37) 13.77 (± 0.32) 
HT29 0.32 (± 0.06) 0.75 (± 0.24) 0.48 (± 0.07) 0.82 (± 0.27) 1.55 (± 0.13) 0.56 (± 0.20) 12.41 (± 1.75) 
 583 
 584 
 585 
Table 3. Ex vivo biodistribution of organs of naïve (n = 4) and infected mice (n = 4). The mice 586 
were infected with A. fumigatus and after 21 hours of disease progression, they were injected 587 
with 10-12 MBq 89Zr oxalate. Tissues were excised and measured three hours after the injection. 588 
Data are %ID/g, expressed as the mean or as lung-to-muscle ratios ± 1 SD. Significantly 589 
different organs are shown in bold with * (p < 0.05) or ** (p < 0.01). 590 
Organ Näive mice Infected mice 
Blood 10.5 (± 2.7) 8.6 (± 2.8) 
Lung** 6.0 (± 1.1) 11.6 (± 1.8) 
Muscle 1.6 (± 0.5) 1.9 (± 0.2) 
Liver 4.0 (± 0.8) 3.3 (± 0.7) 
Heart 5.8 (± 2.2) 5.6 (± 1.5) 
Kidney 6.1 (± 1.5) 8.3 (± 1.6) 
Stomach* 2.5 (± 0.2) 3.5 (± 0.7) 
Colon* 2.6 (± 0.4) 3.5 (± 0.2) 
Brain 0.5 (± 0.1) 0.5 (± 0.1) 
Spine* 5.0 (± 0.9) 3.8 (± 0.4) 
Femur right 9.9 (± 4.3) 6.6 (± 0.5) 
Femur left 9.0 (± 3.5) 6.5 (± 1.3) 
Lung/muscle 3.8 (± 2.3) 6.3 (± 7.7) 
 591 
 592 
 593 
 594 
 595 
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 598 
 599 
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 601 
 602 
Figure 1. (A) Transferability/dissolution of 89Zr mixtures. The y-axis shows transferability as the 603 
activity in a removed aliquot of 300 µL compared to the theoretical maximum activity removed 604 
from a homogeneous solution, as calculated by the equation transferability = A300µL*(1.3/0.3) / 605 
A1300µL * 100%. n = 3 in all cases, error bars show one standard deviation. (B) Transchelation of 606 
89Zr mixtures to DTPA. Oxalate at both pH values showed fast transchelation, reaching about 607 
90% after 10 minutes, while sucrose and especially the citrates showed a slower shift of the 608 
radioactivity to DTPA. n = 3 in all cases, error bars showing one standard deviation are one-609 
sided to improve legibility. 610 
 611 
 612 
Figure 2. Representative transverse (top lane) and coronal (bottom lane) images of 89Zr-613 
distribution in FaDu and HT29 tumor bearing animals acquired by ten minute static PET scans, 1 614 
h (left) and 45 h (right) after tracer administration (FaDu: 12.47 MBq injected, HT29: 9.40 MBq 615 
injected). Animals were sedated with sevoflurane. White letters on images marks T: tumor; B: 616 
bone; L: liver and K: kidney. 617 
 618 
 619 
Figure 3. Tumor-to-muscle (T/M) and tumor-to-blood (T/B) ratios of injected 89Zr oxalate in 620 
mice bearing FaDu or HT29 tumor xenografts. The blood values are taken as %ID/cm3 of the 621 
heart. The T/M values for both tumor types are seen to rise until 20 h and subsequently stabilize 622 
between 3.0-3.7 for both tumors. T/B values for both tumor types increase until 45 h. Error bars 623 
indicate one standard deviation. n = 3 (FaDu), n = 4 (HT29). 9-15 MBq was administered to each 624 
mouse, 10 min scans were acquired. 625 
 626 
 627 
Figure 4 (A)-(D). PET quantification (%ID/cm3) of organs of naïve and infected mice 3 h, 24 h, 628 
48 h post injection of 89Zr oxalate. (E) Maximum intensity projection (MIP) of a naïve and an 629 
infected mouse at the 48 h time-point, demonstrating the high uptake of 89Zr in the bones. 630 
Injected radioactivity was between 10 and 12 MBq. The mice were sedated with isoflurane and 631 
scanned for 10 minutes. Data are given as %ID/cm3 ± 1 SD.  632 
 633 
Figure 5. Maximum intensity projections (MIP) of PET and fused PET and MR images of naïve 634 
or neutropenic A. fumigatus infected mice. The PET/MR imaging was done three hours after 635 
injection with 89Zr oxalate and 21 hours post infection (p.i.) of the mice with A. fumigatus. 636 
Perfusion effects and thereby enhanced 89Zr oxalate accumulation is seen in the lungs of the A. 637 
fumigatus infected mouse as depicted in the lower lane. The mice were sedated with isoflurane 638 
and scanned for 10 minutes. Injected radioactivity was between 10 and 12 MBq  639 
 640 
Figure 6. PET quantification (%ID/cm3) of tissue ROIs from naïve and infected mice with 641 
advanced disease. The data were taken 24 h post-infection, and 3 h after injection of 89Zr oxalate. 642 
Data are given as %ID/cm3 ± 1 SD. *Tissues are considered statistically significant, with p<0.05. 643 
 644 
 645 
